Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07602426

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of resO™ Bone and Joint Support Postbiotic on Physical Function, Pain Interference, and Mobility in Adults With Joint Discomfort

This randomized, double-blind, placebo-controlled study evaluates the effects of resO™ Bone and Joint Support Postbiotic on physical function, pain interference, mobility, and recovery in adults aged 18-75 years experiencing joint discomfort, stiffness, or reduced mobility.

Participants will be randomized to receive either resO™ or placebo for 4 weeks. Outcomes will be assessed using validated patient-reported outcome measures, including PROMIS Physical Function, PROMIS Pain Interference, Duke Activity Status Index (DASI), International Physical Activity Questionnaire-Short Form (IPAQ-SF), and pain numeric rating scales.

The primary objective is to evaluate whether resO™ improves physical function and reduces pain interference compared with placebo.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Joint Discomfort Mobility Limitation Muscular Diseases Musculoskeletal Diseases Musculoskeletal Pain Neurologic Manifestations Pain Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Able Biolabs LLC

Dallas, Texas, 75247, United States

About this study

Joint discomfort and reduced mobility are associated with impaired physical function, pain interference, and decreased quality of life. Chronic low-grade inflammation and connective tissue degeneration contribute to limitations in daily activities and recovery.

This study evaluates resO™ Bone and Joint Support Postbiotic, a microbiome-informed supplement containing heat-inactivated Lactiplantibacillus plantarum RSB11® HI combined with glucosamine sulfate, chondroitin sulfate, methylsulfonylmethane (MSM), Boswellia serrata extract, curcumin extract, bromelain, and vitamin D3.

This is a prospective, randomized, double-blind, placebo-controlled, parallel-group study conducted remotely using electronic data capture. Approximately 40 participants aged 18-75 years with self-reported joint discomfort, stiffness, or reduced mobility will be randomized 1:1 to receive either resO™ or placebo for 4 weeks.

Primary endpoints include changes from baseline to Week 4 in:

PROMIS Physical Function T-score PROMIS Pain Interference T-score

Secondary endpoints include:

Pain intensity Numeric Rating Scale (NRS) Duke Activity Status Index (DASI) International Physical Activity Questionnaire-Short Form (IPAQ-SF) Activity limitation assessments Musculoskeletal recovery assessments Rescue medication use

Safety and tolerability will be assessed through adverse event monitoring and gastrointestinal tolerability questionnaires.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Provide voluntary signed informed consent Adults aged 18-75 years Self-reported joint discomfort, stiffness, or reduced mobility affecting daily activities In generally good health based on self-reported medical history Agree to maintain stable diet, exercise, and lifestyle patterns throughout the study Able and willing to comply with study procedures and electronic questionnaires Access to smartphone, tablet, or computer with internet access

Exclusion criteria

Chronic inflammatory or autoimmune joint disease requiring immunosuppressive or biologic therapy Recent joint surgery or significant musculoskeletal injury within the past 3 months Current unstable use of prescription medications intended for joint pain or inflammation Regular use of joint-targeting supplements that cannot be discontinued prior to participation Known allergy or intolerance to study product ingredients Participation in another investigational study within the past 30 days Pregnant, planning pregnancy, or breastfeeding Significant uncontrolled medical condition that may interfere with study participation or interpretation of results Inability or unwillingness to comply with study procedures

Treatment and study plan

Placebo

Other

Inactivated supplement

Supplement

Dietary Supplement

Active supplement

Primary outcomes

  1. Change From Baseline to Week 4 in PROMIS Physical Function T-score

    Time frame: Baseline and Week 4

    PROMIS Physical Function Adult Short Form is a validated patient-reported outcome measure assessing physical functioning including walking, climbing stairs, bending, and carrying objects. Scores are standardized as T-scores with a population mean of 50 and standard deviation of 10. Higher scores indicate better physical function.

  2. Changes in gut microbiota composition associated with bone health

    Time frame: 8 weeks

  3. Change From Baseline to Week 4 in PROMIS Pain Interference T-score

    Time frame: Baseline and Week 4

    PROMIS Pain Interference Adult Short Form is a validated patient-reported outcome measure assessing the extent to which pain interferes with daily activities, social participation, and quality of life. Scores are standardized as T-scores with a population mean of 50 and standard deviation of 10. Higher scores indicate greater pain interference.

Secondary outcomes

  1. Change From Baseline to Week 4 in Pain Intensity Numeric Rating Scale (NRS) Score

    Time frame: Baseline, weekly through Week 4, and Week 4

    Pain intensity will be assessed using an 11-point Numeric Rating Scale ranging from 0 (no pain) to 10 (worst imaginable pain).

  2. Change From Baseline to Week 4 in Duke Activity Status Index (DASI) Score

    Time frame: Baseline and Week 4

    The Duke Activity Status Index (DASI) is a validated questionnaire assessing functional capacity and activities of daily living. Scores range from 0 to 58.2, with higher scores indicating greater functional capacity.

  3. Change From Baseline to Week 4 in International Physical Activity Questionnaire-Short Form (IPAQ-SF) MET-minutes/week

    Time frame: Baseline and Week 4

    IPAQ-SF assesses physical activity including walking, moderate activity, vigorous activity, and sedentary behavior. Results are expressed as MET-minutes per week.

Sponsors and collaborators

Lead sponsor

Able Biolabs, LLC

Other

Registry information

Official study title

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of a Postbiotic Supplement (resO) on Bone Health and Activity

Acronym: RESO101

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
May 22, 2026
Registry last updated
May 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.